

# HEALTHY U MEDICAID

## PRIOR AUTHORIZATION REQUEST FORM

### APRETUDE®

**For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.**

**Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:

Height/Weight:

***Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.***

**Product being requested:**  Apretude® (cabotegravir)

Dosing/Frequency: \_\_\_\_\_

#### If the request is for reauthorization, proceed to reauthorization section.

Questions	Yes	No	Comments/Notes
1. Is the request for an at-risk adult or adolescent ( $\geq 35$ kg) to reduce the risk of sexually acquired HIV-1 infection?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
2. Is the member confirmed to be HIV-negative within 30 days prior to initiation of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Does the member have an intolerance or contraindication to emtricitabine and tenofovir disoproxil fumarate (generic Truvada®)?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have documentation of tenofovir disoproxil fumarate induced renal dysfunction?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
5. Did the member have new onset or worsening of renal dysfunction after starting a tenofovir disoproxil fumarate regimen?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
6. Is the member taking any medications that are considered medically necessary and likely to cause or exacerbate renal dysfunction?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
7. Does the member have documentation of renal dysfunction with creatinine clearance $<60$ mL/min?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
8. Does the member have documentation of osteoporosis confirmed by DEXA Scan OR do serial DEXA scans show osteopenia with progression of bone loss?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>

#### REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
---	--------------------------	--------------------------	--

2. Has Aprelude shown to be tolerable and effective?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
3. Does the member have a continued medical need for therapy?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
4. Does the member have a documented negative HIV-1 test every 3 months?	<input type="checkbox"/>	<input type="checkbox"/>	<b>Please provide documentation</b>
<b>What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.</b>			
Additional information:			
Physician Signature:			

**\*\*Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\***

Policy PHARM-HU-134  
 Origination Date: 05/09/2022  
 Reviewed/Revised Date: 05/17/2023  
 Next Review Date: 05/17/2024  
 Current Effective Date: 06/01/2023

**Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.